{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:14:34Z","timestamp":1778130874350,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Potentially resectable, stage IIB\u2013IIIB non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge. Factors such as tumor size, location, or nodal status often preclude initial complete resection, necessitating novel strategies to improve prognosis. While neoadjuvant immunochemotherapy has demonstrated promise in metastatic\/advanced NSCLC, evidence for its application in the potentially resectable setting remains limited. This study synthesizes the existing evidence and evaluates the efficacy, pathological response rates, and frequency of treatment-related events associated with neoadjuvant immunochemotherapy in this specific patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A single-arm meta-analysis was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)-NMA guidelines. A systematic search of databases (PubMed, Embase, and Cochrane) was performed up to 9 December 2025, for studies investigating neoadjuvant anti-PD-1\/PD-L1 therapy combined with chemotherapy in potentially resectable NSCLC. Data were analyzed using STATA 14.\u00a0A random-effects model was employed for significant heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      &amp;gt; 50%); otherwise, a fixed-effects model was used. Sensitivity analyses, Begg\u2019s test\/Egger\u2019s test, and the trim-and-fill method were applied to assess bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 34 studies involving 1,885 patients were included. The pooled surgical resection rate was 76.0% (95% CI: 70.0%\u221282.0%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a089.34%). The R0 resection rate was 100% (95% CI: 99%\u2212100%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0.00%). The pathological complete response (pCR) rate was 35.9% (95% CI: 30.7%\u221241.0%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 13.94%), and the major pathological response (mPR) rate was 25% (95% CI: 21%\u221229%). The combined rate of pCR and mPR was 60.2% (95% CI: 55.1%\u221265.4%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 65.70%). The incidence of grade \u22653 adverse events (AEs) was 9.0% (95% CI: 5.0%\u221214.0%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 82.05%), and the rate of surgical complications was 8.0% (95% CI: 3.0%\u221215.0%;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 82.37%). Sensitivity analyses and the trim-and-fill method supported the robustness of the results, with no significant publication bias detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This single-arm meta-analysis suggests that for patients with potentially resectable NSCLC, neoadjuvant immunochemotherapy followed by surgery shows promising short-term pathological response rates and acceptable rates of treatment-related events, indicating potential feasibility. However, because of the lack of comparator data and mature long-term survival outcomes, its definitive clinical benefit remains uncertain. Our results provide preliminary evidence and rationale for initiating randomized controlled clinical trials in this population to compare the efficacy and safety of surgery after neoadjuvant immunochemotherapy versus current standard therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42024579329.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1826159","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:56:34Z","timestamp":1778129794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of neoadjuvant immunochemotherapy in potentially resectable non-small cell lung cancer: a single-arm meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Fengpin","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Neijiang First People\u2019s Hospital","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Neijiang Hospital of Traditional Chinese Medicine","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongmin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Neijiang First People\u2019s Hospital","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Neijiang First People\u2019s Hospital","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Neijiang First People\u2019s Hospital","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hospital Infection Management, Affiliated Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]},{"name":"Department of Pulmonary and critical care medicine, Affiliated Hospital of Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-103","article-title":"Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma","volume":"13","author":"Shen","year":"2021","journal-title":"J Thorac Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1435","article-title":"Meta-analyses: what is heterogeneity","volume":"350","author":"Sedgwick","year":"2015","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e20526","article-title":"The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21037\/jtd-23-1103","article-title":"Efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in locally advanced non-small cell lung cancer-a retrospective cohort study","volume":"16","author":"Chen","year":"2024","journal-title":"J Thorac Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2021.03.041","article-title":"Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: a retrospective study","volume":"113","author":"Chen","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann Surg"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100240","article-title":"Neoadjuvant durvalumab plus chemotherapy in stage III non-small cell lung cancer: A phase II single-center exploratory study","author":"Dong","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1175","article-title":"Neoadjuvant immunotherapy combined with chemotherapy in the treatment of stage III lung squamous cell carcinoma: a retrospective cohort study","volume":"15","author":"Guo","year":"2023","journal-title":"J Thorac Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/j.jtho.2023.09.465","article-title":"P1. 25\u201311 Phase 2 trial of neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable or potentially resectable NSCLC","volume":"18","author":"Jiang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/j.jtho.2023.09.508","article-title":"P2.01\u201303 Efficiency and survival data of neoadjuvant PD-1 inhibitor combined with chemotherapy in potentially resectable IIIA or IIIB NSCLC","volume":"18","author":"Ma","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.06.005","article-title":"Unresectable stage III NSCLC should not be treated with neoadjuvant therapy and re-evaluated for resection","volume":"18","author":"MoGhanaki","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102422","article-title":"Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial","volume":"68","author":"Sun","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100186","article-title":"82P Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA\/IIIB non-small cell lung cancer (NSCLC)","volume":"16","author":"Wang","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100249","article-title":"137P Tislelizumab combined with chemotherapy as neoadjuvant therapy for stage IIIA-IIIB (N2) potentially resectable squamous non-small-cell lung cancer (TACT)","volume":"16","author":"Shan","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758552","article-title":"The safety and efficacy of preoperative immunotherapy combined with chemotherapy in patients with stage IIIA-IIIB lung squamous cell carcinoma","volume":"71","author":"Wang","year":"2023","journal-title":"Thorac Cardiovasc Surg"},{"key":"B25","article-title":"EP08.02\u201326 Clinical outcome of neoadjuvant of tislelizumab plus chemotherapy for Chinese locally advanced NSCLC patients. Journal of Thoracic Oncology","author":"Wang","year":"2023"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S388777","article-title":"Efficacy and safety of the PD-1 inhibitor combined with albumin-bound paclitaxel and nedaplatin in preoperative neoadjuvant therapy of unresectable stage III lung squamous cell carcinoma","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1400","DOI":"10.1016\/j.annonc.2021.10.082","article-title":"64P Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)","volume":"32","author":"Yan","year":"2021","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S934","DOI":"10.1016\/j.annonc.2021.08.1763","article-title":"1160P Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer, ESMO Congress 2021","volume":"32","author":"Zhang","year":"2021","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtho.2022.07.502","article-title":"EP05.02\u2013021 An updated analysis of toripalimab and platinum-doublet chemotherapy as neoadjuvant therapy for potentially resectable NSCLC, IASLC 2022 WCLC World Conference on Lung Cancer","volume":"17","author":"Zhang","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.339","article-title":"P15.02 Toripalimab and platinum-doublet chemotherapy as neoadjuvant therapy for potentially resectable non-small cell lung cancer, 2021 World Conference on Lung Cancer Worldwide Virtual Event","author":"Zhang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107326","article-title":"Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer","volume":"184","author":"Zheng","year":"2023","journal-title":"Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S942","DOI":"10.1016\/j.annonc.2021.08.1780","article-title":"1176P Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: an open-label, single-arm, phase II trial","volume":"32","author":"Zhu","year":"2021","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-024-01861-w","article-title":"Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transd Targ Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12672-024-01278-5","article-title":"Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer","volume":"15","author":"Huang","year":"2024","journal-title":"Discov Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.12.015","article-title":"Rationale and design of a single-arm, phase 2, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC: The DEDALUS trial","volume":"24","author":"Filippi","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111325","article-title":"Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-369","article-title":"Induction chemoimmunotherapy and surgery for unresectable stage III non-small cell lung cancer","volume":"14","author":"Wang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102997","article-title":"Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial","volume":"79","author":"Yu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479263","article-title":"Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA\/IIIB NSCLC: a retrospective study","volume":"15","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-025-03961-0","article-title":"Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study","volume":"74","author":"Qi","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41467-025-57184-z","article-title":"Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial","volume":"16","author":"Yi","year":"2025","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8024","DOI":"10.1200\/JCO.2024.42.16_suppl.8024","article-title":"A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA\/IIIB non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/S1556-0864(25)00426-5","article-title":"Chemo-immunotherapy for borderline resectable and unresectable NSCLC: 233P","volume":"20","author":"Chaft","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12957-024-03462-x","article-title":"Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer","volume":"23","author":"Yang","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.cllc.2024.11.005","article-title":"Conversion surgery for initially unresectable stage III nonsmall cell lung cancer after induction treatment of immunochemotherapy: a multicenter study","volume":"26","author":"Wang","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100574","article-title":"Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial","volume":"6","author":"Zeng","year":"2025","journal-title":"Med"},{"key":"B48","volume-title":"Joanna Briggs Institute reviewers\u2019 manual: 2014 edition","year":"2014"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31829923ec","article-title":"Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers","volume":"8","author":"Chaft","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezz044","article-title":"Pathological complete response after neoadjuvant\/induction treatment: where is its place in the lung cancer staging system","volume":"56","author":"Melek","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2025.04.002","article-title":"Operative challenges after induction immunotherapy for lung cancer","volume":"35","author":"Hawkins","year":"2025","journal-title":"Thorac Surg Clin"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-1376","article-title":"Influence of neoadjuvant immunotherapy on surgical approaches in non-small cell lung cancer: insights from a Chinese expert questionnaire survey on contemporary practices","volume":"17","author":"Wu","year":"2025","journal-title":"J Thorac Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-1007","article-title":"Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study","volume":"13","author":"Zhang","year":"2021","journal-title":"J Thorac Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-022-01283-7","article-title":"Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients","volume":"15","author":"Zhou","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial, 2023 American Society of Clinical Oncology Annual Meeting, ASCO","volume":"41","author":"Spicer","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1826159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:56:36Z","timestamp":1778129796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1826159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":59,"alternative-id":["10.3389\/fonc.2026.1826159"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1826159","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1826159"}}